Anti-Viral Treatment and Cancer Control

Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 193)


Hepatitis B virus (HBV), hepatitis C virus (HCV), human papillomavirus (HPV), and Epstein–Barr virus (EBV) contribute to about 10–15 % global burden of human cancers. Conventional chemotherapy or molecular target therapies have been used to treat virus-associated cancers. However, a more proactive approach would be the use of antiviral treatment to suppress or eliminate viral infections to prevent the occurrence of cancer in the first place. Antiviral treatments against chronic HBV and HCV infections have achieved this goal, with significant reduction in the incidence of hepatocellular carcinoma in treated patients. Antiviral treatments for EBV, Kaposi’s sarcoma-associated herpesvirus (KSHV), and human T-cell lymphotropic virus type 1 (HTLV-1) had limited success in treating refractory EBV-associated lymphoma and post-transplant lymphoproliferative disorder, KSHV-associated Kaposi’s sarcoma in AIDS patients, and HTLV-1-associated acute, chronic, and smoldering subtypes of adult T-cell lymphoma, respectively. Therapeutic HPV vaccine and RNA-interference-based therapies for treating HPV-associated cervical cancers also showed some encouraging results. Taken together, antiviral therapies have yielded promising results in cancer prevention and treatment. More large-scale studies are necessary to confirm the efficacy of antiviral therapy. Further investigation for more effective and convenient antiviral regimens warrants more attention.


  1. Bazarbachi A, Plumelle Y, Carlos Ramos J, Tortevoye P, Otrock Z, Taylor G, Gessain A, Harrington W, Panelatti G, Hermine O (2010) Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol 28:4177–4183Google Scholar
  2. Benitez-Hess ML, Reyes-Gutierrez P, Alvarez-Salas LM (2011) Inhibition of human papillomavirus expression using DNAzymes. Methods Mol Biol 764:317–335PubMedCrossRefGoogle Scholar
  3. Bermúdez-Humarán LG, Langella P (2010) Perspectives for the development of human papillomavirus vaccines and immunotherapy. Expert Rev Vaccines 9:35–44PubMedCrossRefGoogle Scholar
  4. Besson C, Panelatti G, Delaunay C, Gonin C, Brebion A, Hermine O, Plumelle Y (2002) Treatment of adult T-cell leukemia-lymphoma by CHOP followed by therapy with antinucleosides, alpha interferon and oral etoposide. Leuk Lymphoma 43:2275–2279Google Scholar
  5. Bharti AC, Shukla S, Mahata S, Hedau S, Das BC (2009) Anti-human papillomavirus therapeutics: facts & future. Indian J Med Res 130:296–310PubMedGoogle Scholar
  6. Biver-Dalle C, Nguyen T, Touze A, Saccomani C, Penz S, Cunat-Peultier S, Riou-Gotta MO, Humbert P, Coursaget P, Aubin F (2011) Use of interferon-alpha in two patients with Merkel cell carcinoma positive for Merkel cell polyomavirus. Acta Oncol 50:479–480PubMedCrossRefGoogle Scholar
  7. Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A, Sixbey J, Gresik MV, Carrum G, Hudson M, Dilloo D, Gee A, Brenner MK, Rooney CM, Heslop HE (2004) Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin’s disease. J Exp Med 200:1623–1633PubMedCrossRefGoogle Scholar
  8. Boulet GA, Horvath CA, Berghmans S, Bogers J (2008) Human papillomavirus in cervical cancer screening: important role as biomarker. Cancer Epidemiol Biomarkers Prev 17:810–817PubMedCrossRefGoogle Scholar
  9. Bourboulia D, Aldam D, Lagos D, Allen E, Williams I, Cornforth D, Copas A (2004) Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia. AIDS 18:485–493PubMedCrossRefGoogle Scholar
  10. Bower M, Palmieri C, Dhillon T (2006) AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis 19:14–19PubMedCrossRefGoogle Scholar
  11. Brinkman JA, Hughes SH, Stone P, Caffrey AS, Muderspach LI, Roman LD, Weber JS, Kast WM (2007) Therapeutic vaccination for HPV induced cervical cancers. Dis Markers 23:337–352PubMedCrossRefGoogle Scholar
  12. Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TM, Feinman SV, Mach T, Akarca US, Schutten M, Tielemans W, van Vuuren AJ, Hansen BE, Janssen HL (2008) Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 135:459–467PubMedCrossRefGoogle Scholar
  13. Cammá C, Giunta M, Andreone P, Craxi A (2001) Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 34:593–602PubMedCrossRefGoogle Scholar
  14. Carter JJ, Paulson KG, Wipf GC, Miranda D, Madeleine MM, Johnson LG, Lemos BD, Lee S, Warcola AH, Iyer JG, Nghiem P, Galloway DA (2009) Association of Merkel cell polyomavirus-specific antibodies with Merkel cell carcinoma. J Natl Cancer Inst 101:1510–1522PubMedCrossRefGoogle Scholar
  15. Casper C (2011) The increasing burden of HIV-associated malignancies in resource-limited regions. Annu Rev Med 62:157–170PubMedCrossRefGoogle Scholar
  16. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Hamn KH, Goodman Z, Zho J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D, Group tBAS (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354: 1001–1010Google Scholar
  17. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, Chu HC, Wu TC, Yang SS, Kuo HS, Chen DS (2009) Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 101:1348–1355PubMedCrossRefGoogle Scholar
  18. Chen CJ, Yang HI, Iloeje UH (2009) Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 49:S72–S84PubMedCrossRefGoogle Scholar
  19. Chua D, Huang J, Zheng B, Lau SY, Luk W, Kwong DL, Sham JS, Moss D, Yuen KY, Im SW, Ng MH (2001) Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma. Int J Cancer 94:73–80PubMedCrossRefGoogle Scholar
  20. Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, Schiavo R, Secondino S, Frasson C, Perotti C, Moroni M, Locatelli F, Siena S (2005) Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 23:8942–8949PubMedCrossRefGoogle Scholar
  21. De Paoli P, Pratesi C, Bortolin MT (2007) The Epstein Barr virus DNA levels as a tumor marker in EBV-associated cancers. J Cancer Res Clin Oncol 133:809–815PubMedCrossRefGoogle Scholar
  22. Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio PL, Rizzetto M, Craxi A (2004) Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 40:883–891PubMedGoogle Scholar
  23. Dienstag JL (2009) Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology 49:S112–S121PubMedCrossRefGoogle Scholar
  24. Edwards TG, Koeller KJ, Slomczynska U, Fok K, Helmus M, Bashkin JK, Fisher C (2011) HPV episome levels are potently decreased by pyrrole-imidazole polyamides. Antiviral Res 91:177–186PubMedCrossRefGoogle Scholar
  25. El-Serag HB (2012) Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142:1264–1273.e1Google Scholar
  26. Etoh KI, Yamaguchi K, Tokudome S, Watanabe T, Okayama A, Stuver S, Mueller N, Takatsuki K, Matsuoka M (1999) Rapid quantification of HTLV-1 provirus load: detection of monoclonal proliferation of HTLV-1-infected cells among blood donors. Int J Cancer 81:859–864PubMedCrossRefGoogle Scholar
  27. Faller DV, Mentzer SJ, Perrine SP (2001) Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Curr Opin Oncol 13:360–367PubMedCrossRefGoogle Scholar
  28. Fang CT, Chen PJ, Chen MY, Hung CC, Chang SC, Chang AL, Chen DS (2003) Dynamics of plasma hepatitis B virus levels after highly active antiretroviral therapy in patients with HIV infection. J Hepatol 39:1028–1035PubMedCrossRefGoogle Scholar
  29. Feld JJ, Wong DK, Heathcote EJ (2009) Endpoints of therapy in chronic hepatitis B. Hepatology 49:S96–S102PubMedCrossRefGoogle Scholar
  30. Feng H, Shuda M, Chang Y, Moore PS (2008) Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319:1096–1100PubMedCrossRefGoogle Scholar
  31. Gantt S, Casper C (2011) Human herpesvirus 8-associated neoplasms: the roles of viral replication and antiviral treatment. Curr Opin Infect Dis 24:295–301PubMedCrossRefGoogle Scholar
  32. Ghosh SK, Perrine SP, Faller DV (2012) Advances in virus-directed therapeutics against Epstein-Barr virus-associated malignancies. Adv Virol 2012:509296PubMedGoogle Scholar
  33. Gill PS, Harrington W Jr, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, Bernstein-Singer M, Espina BM, Cabral L, Allen S, Kornblau S, Pike MC, Levine AM (1995) Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 332:1744–1748PubMedCrossRefGoogle Scholar
  34. Gomez-Gutierrez JG, Elpek KG, Montes de Oca-Luna R, Shirwan H, Sam Zhou H, McMasters KM (2007) Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunol Immunother 56:997–1007PubMedCrossRefGoogle Scholar
  35. Goncalves DU, Proietti FA, Ribas JG, Araujo MG, Pinheiro SR, Guedes AC, Carneiro-Proietti AB (2010) Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clin Microbiol Rev 23:577–589PubMedCrossRefGoogle Scholar
  36. Gravitt PE, Kovacic MB, Herrero R, Schiffman M, Bratti C, Hildesheim A, Morales J, Alfaro M, Sherman ME, Wacholder S, Rodriguez AC, Burk RD (2007) High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. Int J Cancer 121:2787–2793PubMedCrossRefGoogle Scholar
  37. Gustafsson Å, Levitsky V, Zou JZ, Frisan T, Dalianis T, Ljungman P, Ringden O, Winiarski J, Ernberg I, Masucci MG (2000) Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 95:807–814PubMedGoogle Scholar
  38. Hermine O, Bouscary D, Gessain A, Turlure P, Leblond V, Franck N, Buzyn-Veil A, Rio B, Macintyre E, Dreyfus F, Bazarbachi A (1995) Treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med 332:1749–1751PubMedCrossRefGoogle Scholar
  39. Hermine O, Allard I, Lévy V, Arnulf B, Gessain A, Bazarbachi A (2002) A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J 3:276–282PubMedCrossRefGoogle Scholar
  40. Hermine O, Dombret H, Poupon J, Arnulf B, Lefrere F, Rousselot P, Damaj G, Delarue R, Fermand JP, Brouet JC, Degos L, Varet B, de The H, Bazarbachi A (2004) Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J 5:130–134PubMedCrossRefGoogle Scholar
  41. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, Bollard CM, Liu H, Wu MF, Rochester RJ, Amrolia PJ, Hurwitz JL, Brenner MK, Rooney CM (2010) Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115:925–935PubMedCrossRefGoogle Scholar
  42. Hofmann WP, Zeuzem S (2011) A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol 8:257–264PubMedGoogle Scholar
  43. Ingiliz P, Rockstroh JK (2012) HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians. Liver Int 32:1194–1199Google Scholar
  44. Israel BF, Kenney SC (2003) Virally targeted therapies for EBV-associated malignancies. Oncogene 22:5122–5130PubMedCrossRefGoogle Scholar
  45. Iwanaga M, Watanabe T, Utsunomiya A, Okayama A, Uchimaru K, Koh KR, Ogata M, Kikuchi H, Sagara Y, Uozumi K, Mochizuki M, Tsukasaki K, Saburi Y, Yamamura M, Tanaka J, Moriuchi Y, Hino S, Kamihira S, Yamaguchi K (2010) Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood 116:1211–1219PubMedCrossRefGoogle Scholar
  46. Janssen HLA, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TMK, Gerken G, de Man RA, Niesters HGM, Zondervan P, Hansen B, Schalm SW (2005) Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365:123–129PubMedCrossRefGoogle Scholar
  47. Jones M, Nunez M (2011) HIV and hepatitis C co-infection: the role of HAART in HIV/hepatitis C virus management. Curr Opin HIV AIDS 6:546–552PubMedCrossRefGoogle Scholar
  48. Jonson AL, Rogers LM, Ramakrishnan S, Downs LS Jr (2008) Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer. Gynecol Oncol 111:356–364PubMedCrossRefGoogle Scholar
  49. Josefsson AM, Magnusson PKE, Ylitalo N, Sørensen P, Qwarforth-Tubbin P, Andersen PK, Melbye M, Adami H-O, Gyllensten UB (2000) Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 355:2189–2193PubMedCrossRefGoogle Scholar
  50. Kchour G, Makhoul NJ, Mahmoudi M, Kooshyar MM, Shirdel A, Rastin M, Rafatpanah H, Tarhini M, Zalloua PA, Hermine O, Farid R, Bazarbachi A (2007) Zidovudine and interferon-alpha treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran. Leuk Lymphoma 48:330–336PubMedCrossRefGoogle Scholar
  51. Kchour G, Tarhini M, Kooshyar MM, El Hajj H, Wattel E, Mahmoudi M, Hatoum H, Rahimi H, Maleki M, Rafatpanah H, Rezaee SA, Yazdi MT, Shirdel A, de The H, Hermine O, Farid R, Bazarbachi A (2009) Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood 113:6528–6532PubMedCrossRefGoogle Scholar
  52. Kean JM, Rao S, Wang M, Garcea RL (2009) Seroepidemiology of human polyomaviruses. PLoS Pathog 5:e1000363PubMedCrossRefGoogle Scholar
  53. Kim WR, Benson JT, Hindman A, Brosgart C, Fortner-Burton C (2007) Decline in the need for liver transplantation for end stage liver disease secondary to hepatitis B in the US [Abstract]. Hepatology 46(Suppl):238AGoogle Scholar
  54. Kimura H, Ito Y, Suzuki R, Nishiyama Y (2008) Measuring Epstein-Barr virus (EBV) load: the significance and application for each EBV-associated disease. Rev Med Virol 18:305–319PubMedCrossRefGoogle Scholar
  55. Koivusalo R, Krausz E, Helenius H, Hietanen S (2005) Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: opposite effect of siRNA in combination with different drugs. Mol Pharmacol 68:372–382PubMedGoogle Scholar
  56. Krasagakis K, Kruger-Krasagakis S, Tzanakakis GN, Darivianaki K, Stathopoulos EN, Tosca AD (2008) Interferon-alpha inhibits proliferation and induces apoptosis of merkel cell carcinoma in vitro. Cancer Invest 26:562–568PubMedCrossRefGoogle Scholar
  57. Kutok JL, Wang F (2006) Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol Mech Dis 1:375–404Google Scholar
  58. Lacombe K, Rockstroh J (2012) HIV and viral hepatitis coinfections: advances and challenges. Gut 61(Suppl 1):i47–i58PubMedCrossRefGoogle Scholar
  59. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L, Group tBAS (2006) Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354:1011–1020Google Scholar
  60. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej B, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA, Group tGS (2007) Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357:2576–2588Google Scholar
  61. Lau GKK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N, Group tPA-aH-PCHBS (2005) Peginterferon alfa-2a, lamivudine, and combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352:2682–2695Google Scholar
  62. Liaw YF (2006) Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir Ther 11:669–679PubMedGoogle Scholar
  63. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J, Group CALMS (2004) Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351:1521–1531Google Scholar
  64. Liu CJ, Chuang WL, Lee CM, Yu ML, Lu SN, Wu SS, Liao LY, Chen CL, Kuo HT, Chao YC, Tung SY, Yang SS, Kao JH, Liu CH, Su WW, Lin CL, Jeng YM, Chen PJ, Chen DS (2009) Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 136:496–504.e3Google Scholar
  65. Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT, Huls MH, Sheehan A, Wu MF, Liu H, Gee A, Brenner MK, Rooney CM, Heslop HE, Gottschalk S (2010) Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother 33:983–990PubMedCrossRefGoogle Scholar
  66. Loyo M, Guerrero-Preston R, Brait M, Hoque MO, Chuang A, Kim MS, Sharma R, Liegeois NJ, Koch WM, Califano JA, Westra WH, Sidransky D (2010) Quantitative detection of Merkel cell virus in human tissues and possible mode of transmission. Int J Cancer 126:2991–2996PubMedGoogle Scholar
  67. Manns A, Miley WJ, Wilks RJ, Morgan OSC, Hanchard B, Wharfe G, Caranston B, Maloney W, Welles SL, Blattner WA, Waters D (1999) Quantitative proviral DNA and antibody levels in the natural history of HTLV-1 infection. J Infect Dis 180:1487–1493PubMedCrossRefGoogle Scholar
  68. Marcellin P, Lau GKK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N, Group tPA-aH-NCHBS (2004) Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351:1206–1217Google Scholar
  69. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F (2008) Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 359:2442–2455Google Scholar
  70. Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Jin R, Gurel S, Lu ZM, Wu J, Popescu M, Hadziyannis S (2009) Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 136:2169–2179.e1–e4Google Scholar
  71. Masarone M, Persico M (2011) Antiviral therapy: why does it fail in HCV-related chronic hepatitis? Expert Rev Anti Infect 9:535–543CrossRefGoogle Scholar
  72. Masuzaki R, Yoshida H, Omata M (2010) Interferon reduces the risk of hepatocellular carcinoma in hepatitis C virus-related chronic hepatitis/liver cirrhosis. Oncology 78(Suppl 1):17–23PubMedCrossRefGoogle Scholar
  73. Matutes E, Taylor GP, Cavenagh J, Pagliuca A, Bareford D, Domingo A, Hamblin M, Kelsey S, Mir N, Reilly JT (2001) Interferon α and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. Br J Haematol 113:779–784PubMedCrossRefGoogle Scholar
  74. Merlo A, Turrini R, Dolcetti R, Zanovello P, Rosato A (2011) Immunotherapy for EBV-associated malignancies. Int J Hematol 93:281–293PubMedCrossRefGoogle Scholar
  75. Mesri EA, Cesarman E, Boshoff C (2010) Kaposi’s sarcoma and its associated herpesvirus. Nat Rev Cancer 10:707–719PubMedCrossRefGoogle Scholar
  76. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F (2003) Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 37:1309–1319PubMedCrossRefGoogle Scholar
  77. Monini P, Sgadari C, Garosso MG, Bellino S, Biagio AD, Toschi E, Bacigalupo S, Sabbatucci M, Cencioni G, Salvi E, Leone P, Ensoli B, Sarcoma tCAoKs (2009) Clinical course of classic Kaposi’s sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir. AIDS 23:534–538Google Scholar
  78. Moore PS, Chang Y (2010) Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer 10:878–889PubMedCrossRefGoogle Scholar
  79. Munir S, Saleem S, Idrees M, Tariq A, Butt S, Rauff B, Hussain A, Badar S, Naudhani M, Fatima Z, Ali M, Ali L, Akram M, Aftab M, Khubaib B, Awan Z (2010) Hepatitis C treatment: current and future perspectives. Virol J 7:296PubMedCrossRefGoogle Scholar
  80. Nakajima H, Takaishi M, Yamamoto M, Kamijima R, Kodama H, Tarutani M, Sano S (2009) Screening of the specific polyoma virus as diagnostic and prognostic tools for Merkel cell carcinoma. J Dermatol Sci 56:211–213PubMedCrossRefGoogle Scholar
  81. Nguyen HQ, Magaret AS, Kitahata MM, van Rompaey SE, Wald A, Casper C (2008) Persistent Kaposi sarcoma in era of highly active antiretroviral therapy: characterizing the predictors of clinical response. AIDS 22:937–945PubMedCrossRefGoogle Scholar
  82. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Häussinger D (1996) Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334:1422–1427PubMedCrossRefGoogle Scholar
  83. Okayama A, Stuver S, Matsuoka M, Ishizaki J, Tanaka G, Kubuki Y, Mueller N, Hsieh CC, Tachibana N, Tsubouchi H (2004) Role of HTLV-1 proviral DNA load and clonality in the development of adult T-cell leukemia/lymphoma in asymptomatic carriers. Int J Cancer 110:621–625PubMedCrossRefGoogle Scholar
  84. Papatheodoridis GV, Papatheodoridis VC, Hadziyannis SJ (2001) Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther 15:689–698PubMedCrossRefGoogle Scholar
  85. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ (2008) Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis 8:167–178PubMedCrossRefGoogle Scholar
  86. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A (2010) Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 53:348–356PubMedCrossRefGoogle Scholar
  87. Perrine SP, Hermine O, Small T, Suarez F, O’Reilly R, Boulad F, Fingeroth J, Askin M, Levy A, Mentzer SJ, Di Nicola M, Gianni AM, Klein C, Horwitz S, Faller DV (2007) A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 109:2571–2578PubMedCrossRefGoogle Scholar
  88. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC (1980) Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 77:7514–7519Google Scholar
  89. Potthoff A, Manns MP, Wedemeyer H (2010) Treatment of HBV/HCV coinfection. Expert Opin Pharmacother 11:919–928PubMedCrossRefGoogle Scholar
  90. Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL (2005) Global epidemiology of HTLV-I infection and associated diseases. Oncogene 24:6058–6068PubMedCrossRefGoogle Scholar
  91. Putral LN, Bywater MJ, Gu W, Saunders NA, Gabrielli BG, Leggatt GR, McMillan NA (2005) RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin. Mol Pharmacol 68:1311–1319Google Scholar
  92. Qu LS, Chen H, Kuai XL, Xu ZF, Jin F, Zhou GX (2012) Effects of interferon therapy on development of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis: A meta-analysis of randomized controlled trials. Hepatol Res 42:782–789Google Scholar
  93. Ratner L, Harrington W, Feng X, Grant C, Jacobson S, Noy A, Sparano J, Lee J, Ambinder R, Campbell N, Lairmore M (2009) Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma. PLoS ONE 4:e4420PubMedCrossRefGoogle Scholar
  94. Rooney CM, Smith CA, Ng CYC, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE (1995) Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345:9–13Google Scholar
  95. Schrama D, Ugurel S, Becker JC (2012) Merkel cell carcinoma: recent insights and new treatment options. Curr Opin Oncol 24:141–149PubMedCrossRefGoogle Scholar
  96. Sima N, Wang S, Wang W, Kong D, Xu Q, Tian X, Luo A, Zhou J, Xu G, Meng L, Lu Y, Ma D (2007) Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells. Gynecol Oncol 106:299–304PubMedCrossRefGoogle Scholar
  97. Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, Sood GK (2010) Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 8:192–199PubMedCrossRefGoogle Scholar
  98. Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P (2010) Viral hepatitis and HIV co-infection. Antiviral Res 85:303–315PubMedCrossRefGoogle Scholar
  99. Straathof KCM, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, Gresik MV, Gee AP, Russell HV, Brenner MK, Rooney CM, Heslop HE (2005) Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 105:1898–1904PubMedCrossRefGoogle Scholar
  100. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL (2008) Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 28:1067–1077PubMedCrossRefGoogle Scholar
  101. Sunil M, Reid E, Lechowicz MJ (2010) Update on HHV-8-associated malignancies. Curr Infect Dis Rep 12:147–154PubMedCrossRefGoogle Scholar
  102. Tolstov YL, Pastrana DV, Feng H, Becker JC, Jenkins FJ, Moschos S, Chang Y, Buck CB, Moore PS (2009) Human Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassays. Int J Cancer 125:1250–1256PubMedCrossRefGoogle Scholar
  103. Toy M, Veldhuijzen IK, De Man RA, Richardus J, Schalm SW (2008) The potential impact of long-term nucleoside therapy on the mortality and morbidity of high viremic chronic hepatitis B [Abstract]. Hepatology 48(Suppl):717AGoogle Scholar
  104. Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, Harrington W Jr, O’Mahony D, Janik JE, Bittencourt AL, Taylor GP, Yamaguchi K, Utsunomiya A, Tobinai K, Watanabe T (2009) Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol 27:453–459PubMedCrossRefGoogle Scholar
  105. van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Darwish Murad S, de Man RA, Schalm SW, Janssen HL (2004) Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 39:804–810PubMedCrossRefGoogle Scholar
  106. Willmes C, Adam C, Alb M, Volkert L, Houben R, Becker JC, Schrama D (2012) Type I and II IFNs inhibit Merkel cell carcinoma via modulation of the Merkel cell polyomavirus T antigens. Cancer Res 72:2120–2128PubMedCrossRefGoogle Scholar
  107. Wong GL, Yiu KK, Wong VW, Tsoi KK, Chan HL (2010) Meta-analysis: reduction in hepatic events following interferon-alfa therapy of chronic hepatitis B. Aliment Pharmacol Ther 32:1059–1068PubMedCrossRefGoogle Scholar
  108. Woodman CB, Collins SI, Young LS (2007) The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 7:11–22PubMedCrossRefGoogle Scholar
  109. Xi LF, Hughes JP, Castle PE, Edelstein ZR, Wang C, Galloway DA, Koutsky LA, Kiviat NB, Schiffman M (2011) Viral load in the natural history of human papillomavirus type 16 infection: a nested case-control study. J Infect Dis 203:1425–1433PubMedCrossRefGoogle Scholar
  110. Yang YF, Zhao W, Zhong YD, Xia HM, Shen L, Zhang N (2009) Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat 16:265–271PubMedCrossRefGoogle Scholar
  111. Yeh ML, Hung CH, Huang JF, Liu CJ, Lee CM, Dai CY, Wang JH, Lin ZY, Lu SN, Hu TH, Yu ML, Kao JH, Chuang WL, Chen PJ, Chen DS (2011) Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses. PLoS ONE 6:e20752PubMedCrossRefGoogle Scholar
  112. Zhang CH, Xu GL, Jia WD, Li JS, Ma JL, Ge YS (2011) Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: a meta-analysis of randomized controlled trials. Int J Cancer 129:1254–1264PubMedCrossRefGoogle Scholar
  113. Zhou J, Peng C, Li B, Wang F, Zhou C, Hong D, Ye F, Cheng X, Lu W, Xie X (2012) Transcriptional gene silencing of HPV16 E6/E7 induces growth inhibition via apoptosis in vitro and in vivo. Gynecol Oncol 124:296–302PubMedCrossRefGoogle Scholar
  114. Zwaveling S, Ferreira Mota SC, Nouta J, Johnson M, Lipford GB, Offringa R, van der Burg SH, Melief CJM (2002) Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 169:350–358PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Institute of Clinical MedicineNational Taiwan UniversityTaipeiTaiwan
  2. 2.Institute of Epidemiology and Preventive MedicineNational Taiwan UniversityTaipeiTaiwan

Personalised recommendations